Comparison of the Emetogenic Potential Between Cisplatin and Carboplatin in Combination with Alkylating Agents

Authors

  • Andreas du Bois Department of Gynecology and Obstetrics, St. Vincen-tius-Krankenhaus, Karlsruhe, Germany; Department of Gynecology and Obstetrics, University Freiburg, Germany
  • Werner Vach Department of Biometry and Medical Statistics, University Freiburg, Germany
  • Christoph Thomssen Department of Gynecology and Obstetrics, Technical University München, Germany
  • Ulrich Karck Department of Gynecology and Obstetrics, University Freiburg, Germany
  • Helmut Madjar Department of Gynecology and Obstetrics, University Freiburg, Germany
  • Heiner Prömpeler Department of Gynecology and Obstetrics, University Freiburg, Germany
  • Hans G. Meerpohl Department of Gynecology and Obstetrics, St. Vincen-tius-Krankenhaus, Karlsruhe, Germany; Department of Gynecology and Obstetrics, University Freiburg, Germany

DOI:

https://doi.org/10.3109/02841869409083931

Abstract

Platinum-based poh chemotherapy is widely used in the treatment of gynecological cancer. Emesis is one of the most disturbing side-effects of platinum therapy. We performed a study to evaluate and compare the emetogenic potential and the different emesis pattern after cisplatin and carboplatin under antiemetic treatment with ondansetron. One hundred and twenty-two patients with either cisplatin-con-taining (n = 70) or carboplatin-containing (n = 52) first-line chemotherapy were included. Treatment with cisplatin led more frequently to emesis and patients suffered from more severe emesis than carboplatin treated patients. Delayed emesis was observed after both platinum analogues but occurred more frequently and lasted longer after cisplatin.

Downloads

Download data is not yet available.

Downloads

Published

1994-01-01

How to Cite

du Bois, A., Vach, W., Thomssen, C., Karck, U., Madjar, H., Prömpeler, H., & Meerpohl, H. G. (1994). Comparison of the Emetogenic Potential Between Cisplatin and Carboplatin in Combination with Alkylating Agents. Acta Oncologica, 33(5), 531–535. https://doi.org/10.3109/02841869409083931